Get the Stockscreener App
7.67
2.54%
-0.20
After Hours:
7.62
-0.05
-0.65%
Artiva Biotherapeutics Inc stock is traded at $7.67, with a volume of 310.02K.
It is down -2.54% in the last 24 hours and down -25.68% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$7.87
Open:
$7.96
24h Volume:
310.02K
Relative Volume:
0.83
Market Cap:
$372.67M
Revenue:
$251.00K
Net Income/Loss:
$-83.87M
P/E Ratio:
-2.2356
EPS:
-3.4309
Net Cash Flow:
$-79.34M
1W Performance:
-10.29%
1M Performance:
-25.68%
6M Performance:
+114.25%
1Y Performance:
+293.33%
1-Day Range:
$7.60
$8.18
1-Week Range:
$7.60
$9.045
52-Week Range:
$1.47
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
7.67 | 382.39M | 251.00K | -83.87M | -79.34M | -3.4309 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Cantor Fitzgerald reiterates Artiva Biotherapeutics stock rating By Investing.com - Investing.com Australia
ARTV Stock Price, Quote & Chart | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock By Investing.com - Investing.com Nigeria
As Griffith retires, Dittrich returns to Amgen, takes CFO role - biocentury.com
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock By Investing.com - Investing.com Nigeria
Artiva names Diego Miralles as president and head of R&D - The Pharma Letter
Artiva Biotherapeutics CMO Subhashis Banerjee sells $63,386 in stock - Investing.com India
Artiva Biotherapeutics COO Jennifer Bush sells $79,178 in stock - Investing.com India
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics CEO Fred Aslan sells $244,252 of stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock - Investing.com India
Artiva Biotherapeutics SVP Heather Raymon sells $27,879 in stock - Investing.com India
Artiva Biotherapeutics officer Christopher Horan sells $63,072 in stock By Investing.com - Investing.com Australia
Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases - Traders Union
Artiva Biotherapeutics announces executive changes and new appointments By Investing.com - Investing.com Nigeria
Artiva to present AlloNK therapy data at EULAR congress - Investing.com India
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases - Yahoo Finance
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head By Investing.com - Investing.com Nigeria
Artiva Biotherapeutics, Inc. Appoints New Principal Financial Officer and President in May 2026 - Minichart
Artiva Biotherapeutics announces executive changes and new appointments - Investing.com
Artiva Biotherapeutics Inc Thad Huston to separate as CFO effective May 22, 2026 - marketscreener.com
Artiva Biotherapeutics Inc Thad Huston To Separate As CFO Effective May 22, 2026 - TradingView
Artiva Biotherapeutics Names Diego Miralles, M.D., as Pres and Head of Research and Development >ARTV - Moomoo
Artiva Biotherapeutics Announces Major Executive Leadership Transitions - TipRanks
Artiva Biotherapeutics appoints Diego Miralles as president, R&D head - Investing.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, ... - Enidnews.com
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development - Yahoo Finance UK
Artiva Biotherapeutics (ARTV) price target increased by 60.00% to 27.74 - MSN
Major Insider Move Signals Big Confidence in Artiva Biotherapeutics - TipRanks
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares By Investing.com - Investing.com Australia
Ra Capital Management acquires $75m in Artiva Biotherapeutics shares - Investing.com
TradingKey - TradingKey
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Raises Target Price to $41 - Moomoo
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating - Moomoo
Business News, Finance News, Stock Market - RTTNews
Cantor Fitzgerald Boosts Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $40.00 - MarketBeat
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 - Investing.com
H.C. Wainwright raises Artiva Biotherapeutics price target to $35 By Investing.com - Investing.com Canada
Artiva Biotherapeutics stock slides despite positive trial data - MSN
Number of shareholders of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Artiva Biotherapeutics Announces $300 Million Equity Offering - The Globe and Mail
Artiva Biotherapeutics: Runway To Fund Operations Into 2Q 2027 >ARTV - Moomoo
Artiva Biotherapeutics Announces Underwriting Agreement and Public Offering of Shares and Pre-Funded Warrants - Minichart
Latham Watkins Advises on Artiva Biotherapeutics Offering of Common Stock and Pre Funded Warrants - Latham & Watkins LLP
Artiva reports clinical trial data for rheumatoid arthritis therapy - Investing.com UK
Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA - Seeking Alpha
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Horan Christopher | Chief Tech Operations Officer |
May 19 '26 |
Sale |
9.01 |
7,002 |
63,073 |
293,450 |
| Bush Jennifer | COO, CLO, Compliance Officer |
May 19 '26 |
Sale |
9.01 |
8,790 |
79,179 |
337,920 |
| Banerjee Subhashis | Chief Medical Officer |
May 19 '26 |
Sale |
9.01 |
7,037 |
63,386 |
144,963 |
| Aslan Fred | Chief Executive Officer |
May 19 '26 |
Sale |
9.01 |
27,116 |
244,253 |
1,535,082 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):